LENS PRESBIA PLC

Presbia to Participate in the 2016 Aegis Capital Growth Conference

Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration that has developed the Presbia Flexivue Microlens™, a propriety optical lens implant for treating the age-related loss of near-vision, announced that Jarett Fenton, Chief Financial Officer of Presbia is scheduled to present at the AEGIS Growth Conference being held September 20th through 22th at the Encore at Wynn Las Vegas. Mr. Fenton will be available for one-on-one meetings at the conference.

“The 2016 AEGIS Growth Conference will provide the investor community with an increased awareness of our solution for near-vision loss,” said Todd Cooper, President and CEO of Presbia. “We look forward to showcasing our results as the best surgical treatment for presbyopia, as well as discuss our commercial expansion strategy into South Korea which has the highest LASIK penetration in the world.”

Details of the presentation are as follows:

Date: Thursday, September 22, 2016

Time: 10:00 a.m. PDT

Room: 1. Life Science

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

EN
20/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PRESBIA PLC

 PRESS RELEASE

Presbia Achieves ISO Medical Device Quality Milestone

DUBLIN--(BUSINESS WIRE)-- Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration, achieved a major milestone towards complying with the revised ISO (International Standards Organization) 13485:2016 by successfully completing the ISO 13485:2016 audit with no major findings. This was an essential step in recertifying under the ISO standard with annual surveillance audits for the next two years. The renewal of the company’s CE Mark has been completed and is valid through 2022. Notified Body NSAI (Na...

 PRESS RELEASE

Presbia to Participate in the XXXVI Congress of the European Society o...

DUBLIN--(BUSINESS WIRE)-- Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration, will participate in the XXXVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe's leading organization for cataract and refractive surgeons, to be held in Vienna, Austria from September 22-26, 2018. “We have made significant progress in 2018, including our submission in the second quarter of 2018 to the U.S. Food and Drug Administration of our Premarket approval containing...

 PRESS RELEASE

Presbia Announces New Management Appointments

DUBLIN--(BUSINESS WIRE)-- Presbia PLC (NASDAQ: LENS, or the “Company”), an ophthalmic device company and leader in near-vision restoration, announced that Casey Lind has been appointed as Chief Operating Officer effective February 12, 2018. As Chief Operating Officer, Ms. Lind is responsible for the Company’s manufacturing, engineering, quality and IT departments. Ms. Lind brings over 30 years of experience, including 29 years at Alcon where she was in senior leadership positions across manufacturing, global supply chain, and research...

 PRESS RELEASE

Presbia Announces Board and Management Changes and Financing Proposal ...

DUBLIN--(BUSINESS WIRE)-- Presbia PLC (NASDAQ: LENS, or the “Company”), an ophthalmic device company and leader in near-vision restoration, announces that it has re-ordered its operational priorities to focus its resources on FDA approval as well as ongoing clinical and commercial efforts in Germany and South Korea. These actions reduce the Company’s cash burn rate by eliminating pre-FDA approval marketing, manufacturing and engineering expenses related to the post-FDA approval U.S. commercial launch of the Presbia Flexivue Microlens™...

 PRESS RELEASE

Presbia to Participate in the XXXV Congress of the European Society of...

DUBLIN--(BUSINESS WIRE)-- Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, will participate at the XXXV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe’s leading organization for cataract and refractive surgeons, to be held in Lisbon, Portugal on October 7th through 11th. The Presbia Flexivue Microlens is currently approved for sale in 42 countries around the world. The company is planning to make its final submission to the FDA before the end...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch